Infantile Hemangioma Clinical Trial
— IHOfficial title:
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, the investigators designed the study for the following purposes: 1, to aware the incidence of infantile hemangioma and understand the related risk factorsin China; 2, to understand the clinical characteristics of infantile hemangioma and the risk factors for complications; 3, to investigate the level of knowledge, treatment options in infant hemangioma in Chinese doctors; 3, to improve the awareness of infantile hemangioma in parents and provide more advice for pregnancy counseling and eugenics.
| Status | Recruiting |
| Enrollment | 10000 |
| Est. completion date | September 2017 |
| Est. primary completion date | September 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A to 12 Months |
| Eligibility |
Inclusion Criteria: - Chinese - The infants within 12 months of age Exclusion Criteria: - Those whoes guardian does not want his data to be collected in this study |
| Country | Name | City | State |
|---|---|---|---|
| China | Zhujiang Hospital | Guangzhou | Guangdong |
| Lead Sponsor | Collaborator |
|---|---|
| Zhujiang Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The incidence rate of infantile hemangioma in China | Data collected by questionnaire of infantile hemangioma, filled by the investigators | about 1 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02505971 -
Nadolol Versus Propranolol in Children With Infantile Hemangiomas
|
Phase 3 | |
| Recruiting |
NCT04288700 -
Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma
|
Phase 4 | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Completed |
NCT01010308 -
Nadolol for Proliferating Infantile Hemangiomas
|
Phase 2 | |
| Completed |
NCT02913612 -
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
|
Phase 2 | |
| Completed |
NCT01673971 -
Optical Tomographic Imaging of Infantile Hemangiomas
|
||
| Recruiting |
NCT03237637 -
Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas
|
Phase 3 | |
| Recruiting |
NCT05479123 -
Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas
|
Phase 4 | |
| Terminated |
NCT01434849 -
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
|
Phase 1 | |
| Completed |
NCT04105517 -
Hemangiol, Post Marketing Surveillance Study
|
||
| Completed |
NCT01512173 -
Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo
|
Phase 2 | |
| Completed |
NCT01056341 -
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04684667 -
''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
|
Phase 2 | |
| Recruiting |
NCT03842631 -
Optimizing Timolol Maleate Treatment of Infantile Hemangioma by Doppler Ultrasound Examination
|